Eccogene is a clinical stage biopharmaceutical company developing small molecule therapeutics for chronic cardiometabolic and inflammatory diseases, utilizing its expertise in translational research and small molecule design. The company aims to provide safer and more effective oral therapies that enhance treatment options for conditions such as obesity and type 2 diabetes.
Funding
$25.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NASZFounders
Product
Problem
Current treatments for chronic cardiometabolic and inflammatory diseases often lack sufficient efficacy or have undesirable side effects, limiting therapeutic options for patients. There is a need for safer and more effective oral therapies that can be used alone or in combination with existing treatments to improve patient outcomes.
Solution
Eccogene is a biopharmaceutical company focused on developing small molecule therapeutics for chronic cardiometabolic and inflammatory diseases. The company leverages its expertise in translational research and small molecule design to create oral therapies with improved efficacy and safety profiles. Eccogene's pipeline includes candidates targeting GLP-1R, THR-β, and SSAO, aiming to address unmet needs in conditions such as obesity, type 2 diabetes, and inflammatory disorders. These assets are designed for optimal pharmacokinetic and pharmacodynamic properties, enabling once-daily dosing and suitability for combination therapies.
Target Audience
The primary target audience includes patients with chronic cardiometabolic and inflammatory diseases, as well as healthcare providers seeking safer and more effective treatment options for these conditions.
Features
- ECC5004: A small molecule GLP-1 receptor agonist (GLP-1RA) in Phase 2b development for metabolic diseases, licensed to AstraZeneca.
- ECC4703: A THR-β agonist in clinical development for metabolic diseases.
- ECC0509: An SSAO inhibitor in clinical development for inflammatory and metabolic diseases.
- Small molecule design expertise to optimize drug properties, including oral bioavailability and safety.
- Focus on developing therapies suitable for combination use with existing treatments like GLP-1 receptor agonists.